TORONTO, ON / ACCESSWIRE / September 23, 2022 / NEXGENRX INC. (“NexgenRx” or the “Company”) is pleased to announce that it has declared a dividend of half a cent per share ($0.005) on all outstanding Series 1 common and preferred shares. This dividend will be payable on or before October 10, 2022 to all shareholders of record as of the close of business on October 3, 2022. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 Series 1 preferred shares issued and outstanding. The common shares will be listed and offered for trading on the TSX Venture Exchange under the symbol “NXG”. The Series 1 Preferred Stock is not listed or traded on any stock exchange.
Ron Loucks, the Company’s President and CEO, stated, “We are very pleased to reward our shareholders with a second dividend this year that reflects our continued positive performance and financial achievements.”
NexgenRx is Canada’s only full-service, independent, third-party administrator and technology solutions provider offering proprietary full front-end, entitlement, enrollment, hourly bank and mobile access capabilities along with state-of-the-art claims decision and full provider network coverage. These combined capabilities enable NexgenRx, Plan Sponsors, to deliver sophisticated health care management and technology applications in a cost-effective SaaS (Software as a Service) model.
NexgenRx is committed to building partnerships with organizations that seek to exceed the expectations of their customers and plan members and provide superior administration and claims processing solutions at a competitive cost. For more information on NexgenRx, visit www.nexgenrx.com.
Caution with forward-looking statements
Except for statements of historical fact, this press release contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” and other similar words, or statements about specific events or conditions, “may,” or “may.” “will” occur. Although management believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that these expectations will prove to be correct. The company cannot guarantee future results, performance or achievements. Consequently, there can be no assurance that actual results will be consistent, in whole or in part, with those set forth in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the time the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the future-seeking information. Risks and other factors that could cause results to differ materially from those projected in the forward-looking information include, among others: uncertainty as to whether the Company’s strategies and business plans will yield anticipated benefits; availability and cost of capital; the ability to identify, develop and achieve commercial success for existing and new products and technologies; the level of expenditure required to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and improvement of the Company’s proprietary software technology; Cyber security risks and the other risks and uncertainties disclosed in the Company’s annual Management’s Discussion and Analysis as filed in the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be considered exhaustive.
The forward-looking information contained in this press release is expressly qualified by this cautionary statement. The Company undertakes no obligation to update any forward-looking information to conform such information to actual results or changes in the Company’s expectations, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on any forward-looking information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the publication.
FOR MORE INFORMATION PLEASE CONTACT:
Ronald C Loucks
President and CEO
Kelly Ehler CPA, CA
SOURCE: NexgenRx Inc.
View source version on accesswire.com: